The Private Equity team advised Avista Pharma Solutions on its definitive agreement to be acquired by Cambrex Corporation for approximately $252 million in total cash consideration. Completion of the transaction is subject to customary closing conditions and is expected to occur during the fourth quarter of 2018.
Avista offers a broad suite of scientifically differentiated services ranging from Active Pharmaceutical Ingredients (API) and drug product development and cGMP manufacturing to stand-alone analytical, microbiology testing and solid state sciences. The acquisition of Avista further strengthens Cambrex’s position as the leading fully integrated small molecule contract development and manufacturing organization (CDMO) across the entire drug lifecycle.
Avista Pharma Solutions, a portfolio company of Ampersand Capital Partners, is a contract development, manufacturing, and testing organization that understands what it takes to rapidly advance products through every stage of development.
For additional details on the acquisition, please read the press release.